Dai Di, Dong Xi-Hua, Cheng Shi-Tong, Zhu Ge, Guo Xiao-Lin
Department of Laboratory Medicine, The First Hospital of China Medical University, Nanjing Street No. 155, Heping District, 110000, Shenyang, People's Republic of China.
Tumour Biol. 2014 Aug;35(8):8209-16. doi: 10.1007/s13277-014-2055-1. Epub 2014 May 22.
We conducted the present meta-analysis of relevant cohort studies to evaluate whether promoter methylation of the high in normal-1 (HIN-1) gene contributes to breast cancer. The MEDLINE (1966 ~ 2013), Cochrane Library (Issue 12, 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), Web of Science (1945 ~ 2013), and Chinese Biomedical (CBM) (1982 ~ 2013) databases were searched without any language restrictions. Meta-analyses were conducted using Stata software (version 12.0; Stata Corporation, College Station, TX, USA). Crude odds ratios (ORs) with their 95 % confidence interval (CI) were calculated. Nine clinical cohort studies that enrolled a total of 693 breast cancer patients were included in the meta-analysis. The results of our meta-analysis demonstrated that HIN-1 methylation frequency in cancer tissue was significantly higher than that of normal and benign tissues (cancer tissue vs. normal tissue: OR = 52.60, 95 % CI = 33.77 ~ 81.92, P < 0.001; cancer tissue vs. benign tissue: OR = 2.38, 95 % CI = 1.53 ~ 3.70, P < 0.001; respectively). Ethnicity-stratified analysis indicated that HIN-1 promoter methylation was correlated with the pathogenesis of breast cancer among both Asians and Caucasians (all P < 0.05). Our findings provide empirical evidence that aberrant HIN-1 promoter methylation may contribute to the pathogenesis of breast cancer. Thus, aberrant HIN-1 promoter methylation could be an independent and important biomarker used in predicting the prognosis and progression of breast cancer.
我们开展了本次相关队列研究的荟萃分析，以评估正常组织高表达基因1（HIN-1）的启动子甲基化是否与乳腺癌有关。检索了MEDLINE（1966年至2013年）、Cochrane图书馆（2013年第12期）、EMBASE（1980年至2013年）、护理学与健康领域数据库（CINAHL，1982年至2013年）、科学引文索引（Web of Science，1945年至2013年）以及中国生物医学文献数据库（CBM，1982年至2013年），检索无任何语言限制。使用Stata软件（版本12.0；美国德克萨斯州大学站市Stata公司）进行荟萃分析。计算粗比值比（OR）及其95%置信区间（CI）。共有693例乳腺癌患者的9项临床队列研究纳入了本次荟萃分析。我们的荟萃分析结果表明，癌组织中HIN-1甲基化频率显著高于正常组织和良性组织（癌组织与正常组织比较：OR = 52.60，95%CI = 33.77至81.92，P < 0.001；癌组织与良性组织比较：OR = 2.38，95%CI = 1.53至3.70，P < 0.001）。按种族分层分析表明，亚洲人和高加索人中HIN-1启动子甲基化均与乳腺癌发病相关（所有P < 0.05）。我们的研究结果提供了经验证据，即异常的HIN-1启动子甲基化可能与乳腺癌发病机制有关。因此，异常的HIN-1启动子甲基化可能是预测乳腺癌预后和进展的一个独立且重要的生物标志物。
